189 related articles for article (PubMed ID: 25487084)
1. Population pharmacokinetics of doripenem in Japanese subjects and Monte-Carlo simulation for patients with renal impairment.
Matsuo Y; Ishibashi T; Kubota R; Wajima T
J Infect Chemother; 2015 Feb; 21(2):123-9. PubMed ID: 25487084
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections.
Lee DH; Kim YK; Jin K; Kang MJ; Joo YD; Kim YW; Moon YS; Shin JG; Kiem S
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223378
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/Pharmacodynamic Analysis for Doripenem Regimens in Intensive Care Unit Patient.
Tanaka R; Sato Y; Goto K; Yasuda N; Ohchi Y; Suzuki Y; Ueno T; Ito K; Kaneko T; Kurogi S; Nonoshita K; Itoh H
Biol Pharm Bull; 2017; 40(8):1226-1231. PubMed ID: 28769004
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.
Nandy P; Samtani MN; Lin R
Antimicrob Agents Chemother; 2010 Jun; 54(6):2354-9. PubMed ID: 20385854
[TBL] [Abstract][Full Text] [Related]
5. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
Roberts JA; Lipman J
Crit Care Med; 2013 Feb; 41(2):489-95. PubMed ID: 23263583
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit.
Bhalodi AA; Keel RA; Quintiliani R; Lodise TP; Nicolau DP; Kuti JL
Ann Pharmacother; 2013 May; 47(5):617-27. PubMed ID: 23585647
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and monte carlo simulations of doripenem in patients with febrile neutropenia.
Stein GE; Kulhanek G; Smith CL; Kuti JL; Nicolau DP; Scharmen A; Farnum C; Tran M; Kalra A; Havlichek DH
Ann Pharmacother; 2012 Oct; 46(10):1281-6. PubMed ID: 23012385
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients.
Chung EK; Fleming MR; Cheatham SC; Kays MB
Ann Pharmacother; 2017 Mar; 51(3):209-218. PubMed ID: 28168884
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.
Ikawa K; Morikawa N; Uehara S; Monden K; Yamada Y; Honda N; Kumon H
Int J Antimicrob Agents; 2009 Mar; 33(3):276-9. PubMed ID: 19095418
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.
Abdul-Aziz MH; Abd Rahman AN; Mat-Nor MB; Sulaiman H; Wallis SC; Lipman J; Roberts JA; Staatz CE
Antimicrob Agents Chemother; 2016 Jan; 60(1):206-14. PubMed ID: 26482304
[TBL] [Abstract][Full Text] [Related]
11. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
Roberts JA; Udy AA; Bulitta JB; Stuart J; Jarrett P; Starr T; Lassig-Smith M; Roberts NA; Dunlop R; Hayashi Y; Wallis SC; Lipman J
J Antimicrob Chemother; 2014 Sep; 69(9):2508-16. PubMed ID: 24879665
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.
Samtani MN; Flamm R; Kaniga K; Nandy P
Antimicrob Agents Chemother; 2010 Jun; 54(6):2360-4. PubMed ID: 20385857
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic analysis of doripenem in elderly patients with nosocomial pneumonia.
Harada M; Inui N; Suda T; Nakamura Y; Wajima T; Matsuo Y; Chida K
Int J Antimicrob Agents; 2013 Aug; 42(2):149-54. PubMed ID: 23684002
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of single-dose doripenem in adults with cystic fibrosis.
Cirillo I; Vaccaro N; Redman R; Black PL; Kearns GL
J Clin Pharmacol; 2012 Nov; 52(11):1645-53. PubMed ID: 22174436
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia.
Jaruratanasirikul S; Wongpoowarak W; Kositpantawong N; Aeinlang N; Jullangkoon M
Int J Antimicrob Agents; 2012 Nov; 40(5):434-9. PubMed ID: 22959555
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics of Doripenem in Pediatric Patients and Monte-Carlo Pharmacokinetic-Pharmacodynamic Simulations for Dosing Regimen Assessment.
Matsuo Y; Ishibashi T; Matsumoto S; Katsube T; Wajima T
J Pharm Sci; 2019 Sep; 108(9):3099-3105. PubMed ID: 30974120
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
Kays MB; Fleming MR; Cheatham SC; Chung EK; Juenke JM
Ann Pharmacother; 2014 Feb; 48(2):178-86. PubMed ID: 24259653
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis.
Rahbar AJ; Lodise TP; Abraham P; Lockwood A; Pai MP; Patka J; Rabinovich M; Curzio K; Chester K; Williams B; Morse B; Chaar M; Huang V; Salomone J
Surg Infect (Larchmt); 2016 Dec; 17(6):675-682. PubMed ID: 27841954
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of doripenem during high volume hemodiafiltration in patients with septic shock.
Tamme K; Oselin K; Kipper K; Low K; Standing JF; Metsvaht T; Karjagin J; Herodes K; Kern H; Starkopf J
J Clin Pharmacol; 2015 Apr; 55(4):438-46. PubMed ID: 25408310
[TBL] [Abstract][Full Text] [Related]
20. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem.
Bhavnani SM; Hammel JP; Cirincione BB; Wikler MA; Ambrose PG
Antimicrob Agents Chemother; 2005 Sep; 49(9):3944-7. PubMed ID: 16127078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
